

Liposphere Ltd. is a female-led, innovative, in-house manufacturing MedTech start-up spun out from the Weizmann Institute of Science in Israel in 2019. The Company has developed an orthopaedic platform technology for treating knee osteoarthritis (OA). Knee OA is a cartilage disorder affecting over 600 million people worldwide. These patients experience pain due to damaged cartilage, leading to disability and poor quality of life. When the damage is most severe, patients undergo total knee replacement surgery. However, by then, patients with minor to moderate cartilage damage are seeking a solution. The current commercially available treatments primarily consist of viscosupplements or corticosteroid injections. However, due to the low effectiveness and various side effects of existing treatment options, knee OA remains a medical unmet need.

Liposphere's technology utilizes water-based boundary lubricants to enable smooth, effortless motion of the major human joints through tissue hydration. The technology is based on the discovery of the Hydration Lubrication Mechanism. Liposphere's main product under development, CCoat<sup>®</sup>, is a clinically effective, local knee joint injectable for the treatment of Osteoarthritis, with European market entry anticipated in 2026.

In a recently completed, double-blinded, randomized clinical trial comparing CCoat to placebo, CCoat<sup>®</sup> has demonstrated superiority in terms of functional improvement, pain reduction, and symptom improvement up to 6 months. A novel solution for rapid onset of pain reduction and long-lasting therapeutic symptomatic benefit!

Liposphere Ltd. is a female-led, innovative, in-house manufacturing MedTech start-up spun out from the Weizmann Institute of Science in Israel in 2019. The Company has developed an orthopaedic platform technology for treating knee osteoarthritis (OA). Knee OA is a cartilage disorder affecting over 600 million people worldwide. These patients experience pain due to damaged cartilage, leading to disability and poor quality of life. When the damage is most severe, patients undergo a total knee replacement surgery. However, by then, patients with minor to moderate cartilage damage are seeking a solution. The current commercially available treatments primarily consist of viscosupplements or corticosteroid injections. However, due to low effectiveness and various side effects, knee OA remains a medical unmet need.

Liposphere's technology utilizes water-based boundary lubricants to enable smooth, effortless motion of the major human joints through tissue hydration. Liposphere's technology is based on the discovery of the **Hydration Lubrication Mechanism**. The main product under development- **CCoat** - is a clinically effective, local knee joint injectable for the treatment of Osteoarthritis, with European market entry anticipated in 2026.

In a recently completed, double-blinded, randomized clinical trial comparing CCoat to placebo, CCoat has demonstrated superiority in terms of functional improvement, pain reduction, and symptom improvement up to 6 months. A novel solution for rapid onset of pain reduction and long-lasting therapeutic symptomatic benefit!